American Cancer Society honors $1 million corporate donors
In addition to honoring four individuals with the ACS Medal of Honor this past weekend at their 96th annual meeting, the American Cancer Society also presented its nationwide Corporate Impact Awards to 16 corporations that, over the past year, made contributions of $1 million or more to the ACS.
Included among this year's honored corporations are three pharmaceutical companies, a pharmacy chain, a health care firm, a pair of high-tech computer companies, and a handful of retail companies. In alphabetical order, they are:
AstraZeneca Pharmaceuticals LP
Best Buy
Curves International
dressbarn inc
HairUWear
International Business Machines (IBM)
Merrill Lynch & Co
Novartis Corporation
Oracle
PartyLite Gifts, Inc
Pfizer Inc
The Pampered Chef, LTD
UAL Corporation and United Airlines
Walgreen Co
Walmart
WellPoint, Inc
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
